AI-driven solution to revolutionize clinical trials and diversify patient recruitment and support

RxPx receives co-investment from DIGITAL to combine digital health AI technology with industry partners to transform the delivery and success of clinical trials worldwide

March 21st, Vancouver – 1 in 3 people worldwide suffer from multiple chronic diseases, such as heart disease, diabetes, and cancer. Bringing new drug therapies to market for these diseases is challenging with 85% of clinical trials struggling to enroll sufficient and diverse enough patient numbers for success. The average clinical trial costs $19M USD and the majority of failed trials are not a result of funding and efficacy, but insufficient recruitment, patient data, management of side effects, and patient education.,

With co-investment from DIGITAL, Canada’s Global Innovation Cluster for digital technologies; RxPx, a global digital health company, is launching an ‘AI Clinical Buddy System’, to leverage artificial intelligence towards enhancing patient recruitment, adherence, diversity, and engagement in clinical trials. The project is an innovative partnership between RxPx and industry leaders OPTT, UMed, Aparito, AxialBridge, the University of British Columbia, York University, and distinguished researchers from the UK and Canada. Using machine learning, as well as persuasive, generative, and predictive AI approaches, the AI Clinical Buddy System provides an opportunity to reduce operation overheads, enhance patient physical and behavioral tracking, and improve adherence, retention, and engagement.

“The ultimate aim of any clinical trial is to bring life-saving therapies to market quickly and safely to help as many patients as possible. By increasing the diversity, personalization, and patient support with the AI Clinical Buddy System, we will be able to help life sciences companies and patient populations worldwide. While we have been developing patient-centric AI technologies for the past 5 years, we’re tremendously excited about this ambitious project and honored to be working alongside industry leaders in this transformative project,” says Lynda Brown-Ganzert, CEO of RxPx.

“DIGITAL is excited to build upon the over 5 years of investments we’ve made in applied AI with this latest announcement,” said Nadia Shaikh-Naeem, Vice President of Programs at DIGITAL. “Led by RxPx, this incredible mix of consortium partners is tackling an increasing imperative for the efficacy and diversity of clinical trials for the development of life-saving solutions. We continue to be proud to co-invest alongside innovators like RxPx and support partnerships such as these that are building on Canada’s global reputation in AI and advancing international commercial pathways for Canadian companies.”

DIGITAL’s co-investment in this project is supported through the Technology Commercialization stream within their specialized Horizon AI program: DIGITAL’s national program that seeks to capture Canada’s economic potential for applied AI. With additional program streams focused on emerging market opportunities and talent development, the Technology Commercialization stream co-invests alongside Canadian industry and academia in AI projects that support the resiliency and sustainability of healthcare systems and advance healthcare in ways that support healthy living, accessibility, and delivering positive outcomes.

The project is launched in collaboration with a consortium of industry leaders and research colleagues in the health and digital health arenas including Axial Bridge, uMed, OPTT Health, Aparito, Caoimhe Vallely-Gilroy Consulting, Dr. Kathleen Martin Ginis (UBC’s Centre for Chronic Disease Prevention and Management), Dr. Maleknaz Nayebi’s research team (AI Lab at the Computer Science Department at York University), and Dr. Mark Toshner (Heart and Lung Research Institute NIHR Clinical Research Facility, Cambridge University).

By partnering with global leaders in the space, the AI Clinical Buddy System’s success has the potential to revolutionize the completion, success, and relevancy of clinical trials toward developing more effective medications and therapies for chronic conditions.

To learn more about  RxPx or our partners collaborating on the AI Clinical Buddy System please Valerie Stachurski at valerie.stachurski@rxpx.health /416-520-6504.

About RxPx: 

RxPx is an innovative, AI-backed, digital health SaaS platform designed specifically for the needs of life sciences. Available in 127 countries and 12 languages, RxPx makes life easier for patients, caregivers, and HCPs and helps customers deliver unparalleled value while differentiating their therapeutic brands. With a ‘No Patient Alone’ mission, the RxPx platform helps streamline specialty therapy workflows and personalized patient support to help life sciences companies deliver safe, scalable, and highly impactful programs for their brands.



DIGITAL, Canada’s Global Innovation Cluster for digital technologies, grows Canadian businesses through the development, adoption, and deployment of Canadian-made technologies and by working with industry to develop a digitally skilled workforce to positively impact lives across our country.

 We bring together businesses, academia, community, and government agencies to solve some of industry and society’s biggest challenges – better and faster than any single organization can do on its own. Through a powerful model that combines cross-sector collaboration, Canadian IP creation, and results-based co-investment, we unlock the potential of Canadian industry to lead and succeed in the digital world.

 Ahead of the curve starts here. For more information, visit digitalsupercluster.ca

About OPTT:

OPTT Health is an Award-winning AI platform that streamlines mental health diagnosis and treatment, proving to lower costs and improve care quality. It enables value-based care providers to deliver efficient mental health services and expand their customer base while partnering with varying health organizations to reach even more users.


About Aparito:

Aparito’s mission is to digitize clinical trials and accelerate drug development by supporting patient-centric clinical trials with the Atom5TM eCOA platform.

The Atom5™ platform is Part 11, GDPR and HIPPA compliant and supports clinical trials at scale with video eCOAs, ePROs, Wearables, Telemedicine, and eConsent in 193 countries and 125 languages to capture more frequent patient-generated data in the clinic and at home.

This moves from relying on sterile, snapshot assessments during clinic visits to continuous, real-time, real-world data utilizing novel eCOA and digital biomarkers.


About uMed:

The uMed platform enhances the efficiency and scale of patient research for healthcare professionals, tackling issues like recruitment speed, high screen failure, dropout rates, and patient diversity. Collaborating with leading pharmaceutical firms and academic experts worldwide, uMed connects over 10 million patients’ EHR records through a growing network of providers in the UK, USA, Australia, and Canada.

About Dr. Maleknaz Nayebi (AI Research group at York University)

Maleknaz Nayebi oversees a large size research lab, focusing on practical software solutions aimed at improving daily life, particularly in digital health and emergency management. Her team uses AI to innovate and test ideas, specializing in analyzing unstructured communications and creating technology for health management and emergency response. Their work, which has attracted over $10 million in grants, is shared widely, benefiting both academia and the general public by emphasizing practical outcomes and community well-being.

About Dr. Kathleen Martin Ginis (UBC)

Dr. Ginis is the director of the Centre for Chronic Disease Prevention and Management as well as the Professor of the Department of Medicine, Division of Physical Medicine and Rehabilitation. Her research frequently appears in the media and has been featured on CBC’s Quirks & Quarks, and in The Globe & Mail, The National Post, The New York Times, “O” The Oprah Magazine, Men’s Health & Fitness, and Shape Magazine, among others.


About Medical Safety Systems Corporate:

Medical Safety Systems Corporate Pty Ltd was founded by four doctors in Australia who needed more effective monitoring and communication tools for patients on specialty medicines. It provides integrated, technology-enhanced patient support and monitoring solutions to enable the seamless delivery of those specialty medicines. Customers from all around the world (North America, Australia, and Europe)  utilize the company’s agile technology solutions to monitor patient safety, automate risk management, and streamline access to real-time information to accelerate time to therapy while improving the patient experience. The Company collects a variety of data benefiting their customers in making informed decisions. The Company’s flexible, integrated platform offers pharma manufacturers superior digital patient support and monitoring solutions.

About AxialBridge:

AxialBridge boasts over 15 years of expertise in Clinical Trial Management, Regulatory Affairs, Quality Management, and Strategic Advisory Services in the Life Sciences, specializing in Phase I-IV clinical trials. Their experts offer strategic services to a variety of stakeholders across the biotech and medtech industries, including conducting due diligence for investors. Known for blending innovation with experience to support clients from initial concept to market, the Canadian company extends its global reach through a network in the UK, and United States along with a roster of expert advisors and research partners, establishing itself as a prominent force in clinical trial strategy and innovation.


About Dr. Mark Toshner: Dr. Toshner is the director of the VPD Heart & Lung Research Institute NIHR Clinical Research Facility. He is also an Associate Professor in Translational Respiratory Medicine at the University of Cambridge and an Honorary Consultant at Royal Papworth and Cambridge University Hospital NHS Trusts.


About Caoimhe Vallely-Gilroy Consulting: Specializes in integrating pharmacogenetics, pharmacogenomics, and biomarkers into both early and late phase clinical trials. The team possesses a deep understanding of drug development, CRO contracting, and the regulatory landscapes for both pre-and post-authorization compounds, positioning us at the forefront of pharmaceutical consultancy.



For further information contact: 

Valerie Stachurski, General Manager of Marketing, RxPx

Phone 416-520-9504

Email: valerie.stachurski@rxpx.health


Sydney Redpath, Director of Communications


[1] Hajat, C., & Stein, E. (2018). The global burden of multiple chronic conditions: A narrative review. Preventive Medicine Reports, 12, 284–293. https://doi.org/10.1016/j.pmedr.2018.10.008

[2] Decentralized clinical trials: Are we ready to make the leap? (2019). BioPharma Dive. Retrieved March 11, 2024, from https://www.biopharmadive.com/spons/decentralized-clinical-trials-are-we-ready-to-make-the-leap/546591/

[3] Cost of Clinical Trials For New Drug FDA Approval Are Fraction of Total Tab | Johns Hopkins | Bloomberg School of Public Health. (2018, September 24). https://publichealth.jhu.edu/2018/cost-of-clinical-trials-for-new-drug-FDA-approval-are-fraction-of-total-tab

[4] Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemporary Clinical Trials Communications, 11, 156–164. https://doi.org/10.1016/j.conctc.2018.08.001